Review Article | Published:

Kaposi's sarcoma and its associated herpesvirus

Nature Reviews Cancer volume 10, pages 707719 (2010) | Download Citation

Abstract

Kaposi's sarcoma (KS) is the most common cancer in HIV-infected untreated individuals. Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8 (HHV8)) is the infectious cause of this neoplasm. In this Review we describe the epidemiology of KS and KSHV, and the insights into the remarkable mechanisms through which KSHV can induce KS that have been gained in the past 16 years. KSHV latent transcripts, such as latency-associated nuclear antigen (LANA), viral cyclin, viral FLIP and viral-encoded microRNAs, drive cell proliferation and prevent apoptosis, whereas KSHV lytic proteins, such as viral G protein-coupled receptor, K1 and virally encoded cytokines (viral interleukin-6 and viral chemokines) further contribute to the unique angioproliferative and inflammatory KS lesions through a mechanism called paracrine neoplasia.

Key points

  • Kaposi's sarcoma herpesvirus (KSHV; also known as human herpesvirus 8 (HHV8)) is the causative agent of Kaposi's sarcoma (KS) and certain lymphoproliferations, and its seroepidemiology correlates with the global incidence of KS.

  • KS is the most common neoplasm in untreated HIV-infected individuals, and also occurs in other states of immunosuppression, including after an organ transplant.

  • KSHV is transmitted through saliva and replicates in oropharyngeal cells.

  • Unlike most cancer cells, KS tumour cells are not fully transformed, do not show autonomous growth, and remain dependent on exogenous cytokines for in vitro growth.

  • KS starts as a proliferation of endothelial-type cells, with an early onset inflammatory and abnormal leaky blood vessel expansion.

  • KSHV is present in the vast majority of KS tumour cells (that is, spindle cells), expressing the latent viral proteins, including viral cyclin, viral FLICE inhibitory protein, latency-associated nuclear antigen (LANA) and a group of viral microRNAs.

  • A proportion of cells in KS lesions seem to undergo lytic replication, expressing lytic viral proteins including K1, viral interleukin-6, viral BCL-2, viral G protein-coupled receptor, K15 and viral chemokines.

  • KSHV latent genes drive cell proliferation and prevent apoptosis; whereas KSHV lytic genes could further contribute to KS tumorigenesis by triggering host signalling cascades that lead to cytokine and growth factor secretion.

  • Biological insights into KSHV oncogenesis are leading to promising rational therapeutic approaches.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Idiopathisches multiples Pigmentsarkom der Haut. Arch. Dermatol. Syph. 4 (1872). Original description of KS.

  2. 2.

    Centers for Disease Control. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb. Mortal. Wkly Rep. 30, 305–308 (1981).

  3. 3.

    et al. A preliminary communication on extensively disseminated Kaposi's sarcoma in young homosexual men. Am. J. Dermatopathol. 3, 111–114 (1981).

  4. 4.

    et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871 (1983).

  5. 5.

    et al. Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS. Science 220, 862–865 (1983).

  6. 6.

    & Cloning the differences between two complex genomes. Science 259, 946–951 (1993).

  7. 7.

    et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865–1869 (1994). The molecular discovery of KS-associated herpesvirus.

  8. 8.

    Oncogenic DNA viruses. Oncogene 20, 7820–7823 (2001).

  9. 9.

    et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl Acad. Sci. USA 93, 14862–14867 (1996). The original description of the KSHV genome.

  10. 10.

    The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030–3044 (2006).

  11. 11.

    et al. Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998–2003. Pediatr. Blood Cancer 48, 515–520 (2007).

  12. 12.

    et al. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22, 937–945 (2008).

  13. 13.

    The enigmas of Kaposi's sarcoma. Science 282, 1837–1839 (1998).

  14. 14.

    Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Unio Int. Contra Cancrum 18, 330–363 (1962).

  15. 15.

    , , & Kaposi's sarcoma in East African children: a report of 51 cases. J. Pathol. 100, 187–199 (1970).

  16. 16.

    , , & Disseminated lymphadenopathic Kaposi's sarcoma in Zambian children. Med. J. Zambia 14, 61–63 (1980).

  17. 17.

    et al. Disseminated visceral Kaposi's sarcoma. Appearance after human renal homograft operation. JAMA 207, 1493–1496 (1969). First description of KS from New York, USA, after an organ transplant.

  18. 18.

    , , & Cancer in Kampala, Uganda, in 1989–1991: changes in incidence in the era of AIDS. Int. J. Cancer 54, 26–36 (1993).

  19. 19.

    et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS. J. Infect. Dis. 178, 1787–1790 (1998).

  20. 20.

    et al. Seroepidemiology and molecular epidemiology of Kaposi's sarcoma-associated herpesvirus among Jewish population groups in Israel. J. Natl Cancer Inst. 93, 194–202 (2001).

  21. 21.

    et al. Mucosal shedding of human herpesvirus 8 in men. N. Engl. J. Med. 343, 1369–1377 (2000).

  22. 22.

    et al. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. Int. J. Cancer 120, 1129–1135 (2007).

  23. 23.

    , , , & Wild-type Kaposi's sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells. J. Virol. 78, 4074–4084 (2004).

  24. 24.

    , , & Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335, 123–128 (1990). One of the first studies to highlight that KS could be caused by an infectious agent other than HIV.

  25. 25.

    et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N. Engl. J. Med. 338, 948–954 (1998).

  26. 26.

    et al. Part I: cancer in indigenous Africans-burden, distribution, and trends. Lancet Oncol. 9, 683–692 (2008).

  27. 27.

    et al. Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol. Biomarkers Prev. 15, 926–934 (2006).

  28. 28.

    et al. Susceptibility to human herpesvirus-8 infection in a healthy population from Sardinia is not directly correlated with the expression of HLA-DR alleles. Br. J. Dermatol. 151, 247–249 (2004).

  29. 29.

    et al. HLA-B, -DRB1/3/4/5, and -DQB1 gene polymorphisms in human immunodeficiency virus-related Kaposi's sarcoma. J. Med. Virol. 76, 302–310 (2005).

  30. 30.

    et al. The interleukin-6-174 promoter polymorphism is associated with a risk of development of Kaposi's sarcoma in renal transplant recipients. Anticancer Res. 24, 1311–1314 (2004).

  31. 31.

    et al. Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood 95, 2386–2390 (2000).

  32. 32.

    Disseminated Kaposi's sarcoma syndrome in young homosexual men. J. Am. Acad. Dermatol. 5, 468–471 (1981). One of the original descriptions of KS from New York, USA, heralding the AIDS pandemic.

  33. 33.

    et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann. Intern. Med. 103, 744–750 (1985).

  34. 34.

    , & AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 15, 3085–3092 (1997).

  35. 35.

    et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 22, 1019–1028 (2008).

  36. 36.

    et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 58, 1599–1604 (1998).

  37. 37.

    et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl Acad. Sci. USA 96, 4546–4551 (1999). First antibody-based study to describe the distribution of latent KSHV in KS, PEL and multicentric Castleman's disease.

  38. 38.

    , & Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS 6, 895–913 (1992).

  39. 39.

    Ultrastructure of Kaposi sarcoma. Ultrastruct. Pathol. 32, 211–220 (2008).

  40. 40.

    et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nature Genet. 36, 683–685 (2004).

  41. 41.

    et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nature Genet. 36, 687–693 (2004).

  42. 42.

    , & Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am. J. Pathol. 119, 294–300 (1985).

  43. 43.

    et al. Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 84, 2711–2720 (1994).

  44. 44.

    , & Susceptibility of human fetal mesenchymal stem cells to Kaposi sarcoma-associated herpesvirus. Blood 104, 2736–2738 (2004).

  45. 45.

    et al. Peripheral blood endothelial progenitors as potential reservoirs of Kaposi's sarcoma-associated herpesvirus. PLoS ONE 3, e1520 (2008).

  46. 46.

    et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nature Med. 9, 554–561 (2003). Study proposes that KS tumour cells could be transmitted during an organ transplant.

  47. 47.

    & Kaposi's sarcoma occurring in a dermatome previously involved by herpes zoster. J. Am. Acad. Dermatol. 18, 448–451 (1988).

  48. 48.

    Pathogenesis of HIV-related Kaposi's sarcoma. Curr. Opin. Oncol. 6, 497–502 (1994).

  49. 49.

    et al. Biology of Kaposi's sarcoma. Eur. J. Cancer 37, 1251–1269 (2001).

  50. 50.

    & Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu. Rev. Immunol. 3, 477–500 (1985).

  51. 51.

    et al. Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 242, 430–433 (1988). One of the first studies to suggest that KS tumour cells secrete and are dependent on angiogenic factors for survival.

  52. 52.

    et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 255, 1432–1434 (1992).

  53. 53.

    et al. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc. Natl Acad. Sci. USA 91, 5281–5285 (1994).

  54. 54.

    et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl Acad. Sci. USA 94, 979–984 (1997).

  55. 55.

    et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N. Engl. J. Med. 336, 988–993 (1997).

  56. 56.

    et al. Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc. Natl Acad. Sci. USA 95, 8257–8261 (1998).

  57. 57.

    et al. Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J. Natl Cancer Inst. 99, 1086–1094 (2007).

  58. 58.

    , , , & Gene amplification and multiple mutations of the K-ras oncogene in Kaposi's sarcoma. Anticancer Res. 14, 921–926 (1994).

  59. 59.

    , & Bcl-2 and p53 immunoprofile in Kaposi's sarcoma. Pathol. Oncol. Res. 5, 17–20 (1999).

  60. 60.

    et al. CGH of microdissected Kaposi's sarcoma lesions reveals recurrent loss of chromosome Y in early and additional chromosomal changes in late tumour stages. AIDS 20, 1805–1812 (2006).

  61. 61.

    et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85, 552–565 (1995).

  62. 62.

    , & Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J. Exp. Med. 191, 417–422 (2000).

  63. 63.

    et al. KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo. Blood 108, 141–151 (2006).

  64. 64.

    et al. Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J. Virol. 73, 6892–6902 (1999).

  65. 65.

    et al. Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells. Proc. Natl Acad. Sci. USA 107, 10696–10701 (2010).

  66. 66.

    et al. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 394, 588–592 (1998).

  67. 67.

    et al. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J. Virol. 75, 5614–5626 (2001).

  68. 68.

    et al. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J. Virol. 81, 3980–3991 (2007).

  69. 69.

    et al. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J. Virol. 82, 1759–1776 (2008).

  70. 70.

    et al. Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J. Virol. 83, 3342–3364 (2009).

  71. 71.

    et al. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog. 6, e1000777 (2010).

  72. 72.

    et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71, 715–719 (1997). Analysis of KSHV latent and lytic gene expression in KS spindle cells.

  73. 73.

    , , , & Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J. Virol. 79, 14371–14382 (2005).

  74. 74.

    & Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 84, 5565–5573 (2010).

  75. 75.

    et al. Activation of human herpesvirus 8 open reading frame K5 independent of ORF50 expression. Virus Res. 90, 77–89 (2002).

  76. 76.

    , , , & Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186–1191 (1995). Original study describing the association of KSHV with PEL.

  77. 77.

    et al. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc. Natl Acad. Sci. USA 95, 10866–10871 (1998).

  78. 78.

    , & Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284, 641–644 (1999). Analysis of the role of LANA in maintaining the KSHV episome.

  79. 79.

    et al. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res. 64, 4790–4799 (2004).

  80. 80.

    Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nature Rev. Immunol. 7, 391–401 (2007).

  81. 81.

    & Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. Trends Microbiol. 17, 119–129 (2009).

  82. 82.

    , , & p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402, 889–894 (1999).

  83. 83.

    & Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J. Virol. 80, 697–709 (2006).

  84. 84.

    , & The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nature Med. 6, 1121–1127 (2000).

  85. 85.

    et al. A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nature Med. 9, 300–306 (2003).

  86. 86.

    et al. KSHV LANA inhibits TGF-β signaling through epigenetic silencing of the TGF-β type II receptor. Blood 111, 4731–4740 (2008).

  87. 87.

    , , , & EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2, e116 (2006).

  88. 88.

    , & Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 78, 10348–10359 (2004).

  89. 89.

    et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J. Virol. 77, 6188–6196 (2003).

  90. 90.

    et al. Cyclin encoded by KS herpesvirus. Nature 382, 410 (1996). First characterization of the viral-encoded cyclin, revealing that vcyclin could function as a D type cyclin.

  91. 91.

    et al. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J. Virol. 71, 4193–4198 (1997).

  92. 92.

    & Viral cyclins. Rev. Med. Virol. 10, 175–184 (2000).

  93. 93.

    et al. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nature Cell Biol. 2, 819–825 (2000).

  94. 94.

    , , & The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2, 229–241 (2002).

  95. 95.

    et al. p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nature Cell Biol. 10, 723–730 (2008).

  96. 96.

    et al. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog. 6, e1000818 (2010).

  97. 97.

    et al. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Iκ B kinase complex. J. Biol. Chem. 277, 13745–13751 (2002).

  98. 98.

    et al. Crystal structure of a vFlip-IKKγ complex: insights into viral activation of the IKK signalosome. Mol. Cell 30, 620–631 (2008).

  99. 99.

    , , & Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-κB activation. Oncogene 25, 2717–2726 (2006).

  100. 100.

    , , & Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells. J. Virol. 83, 2140–2153 (2009).

  101. 101.

    , & KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199, 993–1003 (2004).

  102. 102.

    et al. FLIP-mediated autophagy regulation in cell death control. Nature Cell Biol. 11, 1355–1362 (2009).

  103. 103.

    , , & Activation of NF-κB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J. Virol. 80, 7179–7185 (2006).

  104. 104.

    et al. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J. Virol. 73, 5722–5730 (1999).

  105. 105.

    et al. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J. Virol. 72, 4980–4988 (1998).

  106. 106.

    & The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307, 739–741 (2005).

  107. 107.

    et al. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J. Natl Cancer Inst. 94, 926–935 (2002).

  108. 108.

    et al. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 64, 581–589 (2004).

  109. 109.

    et al. Constitutive NF-κB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc. Natl Acad. Sci. USA 102, 12885–12890 (2005).

  110. 110.

    , , & The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J. Clin. Invest. 116, 735–742 (2006).

  111. 111.

    et al. Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter. Blood 105, 2356–2363 (2005).

  112. 112.

    et al. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl Acad. Sci. USA 102, 5570–5575 (2005).

  113. 113.

    et al. Identification of microRNAs of the herpesvirus family. Nature Methods 2, 269–276 (2005).

  114. 114.

    , , & Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79, 9301–9305 (2005). References 112, 113 and 114 described the identification of KSHV-encoded miRNAs.

  115. 115.

    et al. NF-κB inhibits γherpesvirus lytic replication. J. Virol. 77, 8532–8540 (2003).

  116. 116.

    et al. Regulation of NF-κB inhibitor IκBα and viral replication by a KSHV microRNA. Nature Cell Biol. 12, 193–199 (2010).

  117. 117.

    et al. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog. 3, e65 (2007).

  118. 118.

    et al. KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev. 24, 195–205 (2010).

  119. 119.

    et al. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Natures Cell Biol. 12, 513–519 (2010).

  120. 120.

    et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Med. 16, 909–914 (2010).

  121. 121.

    , , , & Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385, 347–350 (1997).

  122. 122.

    et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391, 86–89 (1998). References 121 and 122 report the initial charaterization of the vGPCR.

  123. 123.

    et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res. 60, 4873–4880 (2000).

  124. 124.

    et al. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 67, 4042–4051 (2007).

  125. 125.

    & Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-κ B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J. Immunol. 167, 505–513 (2001).

  126. 126.

    et al. Constitutive activation of NF-κ B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve Gα13 and RhoA. J. Biol. Chem. 276, 45979–45987 (2001).

  127. 127.

    et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J. Exp. Med. 191, 445–454 (2000).

  128. 128.

    et al. Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J. Virol. 77, 2631–2639 (2003).

  129. 129.

    et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J. Clin. Invest. 116, 1264–1273 (2006).

  130. 130.

    et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3, 23–36 (2003).

  131. 131.

    et al. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood 104, 2903–2911 (2004).

  132. 132.

    et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 10, 133–143 (2006).

  133. 133.

    et al. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc. Natl Acad. Sci. USA 106, 8683–8688 (2009).

  134. 134.

    et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nature Med. 3, 287–292 (1997).

  135. 135.

    et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93, 4034–4043 (1999).

  136. 136.

    et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278, 290–294 (1997).

  137. 137.

    et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 95, 1151–1157 (2000).

  138. 138.

    , , , & Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nature Med. 3, 293–298 (1997).

  139. 139.

    et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc. Natl Acad. Sci. USA 94, 690–694 (1997). References 138 and 139 characterized the viral encoded BCL-2.

  140. 140.

    & BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2. Cell Death Differ. 15, 580–588 (2008).

  141. 141.

    , , , & Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J. Virol. 75, 6193–6198 (2001).

  142. 142.

    et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J. Virol. 80, 2257–2266 (2006).

  143. 143.

    , , , & Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 α to induce vascular endothelial growth factor expression. Cancer Res. 68, 1751–1759 (2008).

  144. 144.

    & The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J. Virol. 78, 1918–1927 (2004).

  145. 145.

    et al. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. J. Natl Cancer Inst. 101, 399–411 (2009).

  146. 146.

    et al. Activation of mitogen-activated protein kinase and NF-κB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J. Virol. 77, 9346–9358 (2003).

  147. 147.

    , , , & Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. J. Virol. 81, 42–58 (2007).

  148. 148.

    & Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Mol. Cell 13, 713–723 (2004).

  149. 149.

    et al. Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. AIDS 11, F35–F45 (1997).

  150. 150.

    et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 340, 1063–1070 (1999). Clinical study indicating that anti-herpesviral agents could prevent KS development.

  151. 151.

    et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J. Virol. 76, 2634–2640 (2002).

  152. 152.

    et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18, 485–493 (2004).

  153. 153.

    & Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Invest. 113, 124–136 (2004).

  154. 154.

    et al. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res. 66, 168–174 (2006).

  155. 155.

    , , , & Antitumour effects of antiretroviral therapy. Nature Rev. Cancer 4, 861–875 (2004).

  156. 156.

    , & AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr. Opin. Infect. Dis. 19, 14–19 (2006).

  157. 157.

    , & Signal transduction targets in Kaposi's sarcoma. Curr. Opin. Oncol. 18, 456–462 (2006).

  158. 158.

    & Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr. Opin. Oncol. 19, 452–457 (2007).

  159. 159.

    et al. KSHV manipulates Notch signaling by DLL4 and JAG1 to alter cell cycle genes in lymphatic endothelia. PLoS Pathog. 5, e1000616 (2009).

  160. 160.

    et al. γ secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24, 6333–6344 (2005).

  161. 161.

    et al. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 115, 887–895 (2010).

  162. 162.

    KSHV strains: the origins and global spread of the virus. Semin. Cancer Biol. 9, 187–199 (1999).

  163. 163.

    & Actin dynamics regulate multiple endosomal steps during Kaposi's sarcoma-associated herpesvirus entry and trafficking in endothelial cells. PLoS Pathog. 5, e1000512 (2009).

  164. 164.

    , , , & Characterization of Kaposi sarcoma-associated herpesvirus/human herpesvirus-8 infection of human vascular endothelial cells: early events. Blood 100, 888–896 (2002).

  165. 165.

    et al. Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc. Natl Acad. Sci. USA 98, 4119–4124 (2001).

  166. 166.

    , , & Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R. protein. Virology 252, 304–312 (1998).

  167. 167.

    & Murine γherpesvirus 68: a model for the study of γherpesvirus pathogenesis. Trends Microbiol. 6, 276–282 (1998).

  168. 168.

    et al. Rhesus macaque rhadinovirus-associated non-Hodgkin lymphoma: animal model for KSHV-associated malignancies. Blood 112, 4227–4234 (2008).

  169. 169.

    et al. High levels of retroperitoneal fibromatosis (RF)-associated herpesvirus in RF lesions in macaques are associated with ORF73 LANA expression in spindleoid tumour cells. J. Gen. Virol. 87, 3529–3538 (2006).

  170. 170.

    et al. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J. Virol. 80, 4833–4846 (2006).

  171. 171.

    et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 11, 245–258 (2007). A KSHV-BAC-infected line induces lesions resembling KS in a murine model.

  172. 172.

    et al. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J. Exp. Med. 190, 1857–1868 (1999).

  173. 173.

    et al. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J. Clin. Invest. 116, 1963–1973 (2006).

  174. 174.

    et al. Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection. PLoS Pathog. 5, e1000606 (2009).

  175. 175.

    & AIDS-related malignancies. Nature Rev. Cancer 2, 373–382 (2002).

  176. 176.

    et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 68, 4754–4762 (2008).

  177. 177.

    , , & A Kaposi's sarcoma complete clinical response after sorafenib administration. Ann. Oncol. 19, 1658–1659 (2008).

  178. 178.

    , , , & Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am. J. Pathol. 156, 2179–2183 (2000).

  179. 179.

    et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J. Virol. 76, 8383–8399 (2002).

  180. 180.

    et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 23, 982–989 (2005).

  181. 181.

    et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352, 1317–1323 (2005). Original description of striking responses of KS lesions after treatment with an mTOR inhibitor.

  182. 182.

    , & Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions. J. Natl Cancer Inst. 49, 1509–1526 (1972).

  183. 183.

    , , , & The FGF-related oncogene, K-FGF, maps to human chromosome region 11q13, possibly near int-2. Oncogene Res. 3, 263–270 (1988).

  184. 184.

    et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86, 2708–2714 (1995).

  185. 185.

    et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86, 1276–1280 (1995). First paper to link KSHV to the pathogenesis of multicentric Castleman's disease.

  186. 186.

    et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Med. 1, 1274–1278 (1995). Original paper showing KSHV is present in each tumour (spindle cell) in KS lesions.

  187. 187.

    et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nature Med. 2, 342–346 (1996). First paper describing in vitro lytic growth of the virus.

  188. 188.

    et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nature Med. 2, 925–928 (1996).

  189. 189.

    et al. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nature Med. 2, 918–924 (1996).

  190. 190.

    , , & Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274, 1739–1744 (1996).

  191. 191.

    et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J. Virol. 71, 839–842 (1997).

  192. 192.

    & Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl Acad. Sci. USA 97, 8051–8056 (2000).

  193. 193.

    et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 13, 365–374 (2000).

  194. 194.

    , , , & Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 74, 5300–5309 (2000). References 192, 193 and 194 characterized ORFs K3 and K5, which led to the discovery of cellular MIR proteins.

  195. 195.

    , , & Integrin α3β1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 108, 407–419 (2002).

  196. 196.

    , & The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-κ B activation. Blood 101, 1956–1961 (2003).

  197. 197.

    & Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT. Science 311, 1921–1924 (2006).

Download references

Acknowledgements

E.A.M. is supported by US National Institutes of Health grants CA75918 and CA136387, and C.B. by Cancer Research UK, the Medical Research Council and the University College London and University College London Hopsitals Comprehensive Biomedical Research Centre.

Author information

Affiliations

  1. Viral Oncology Program, Developmental Center for AIDS Research, and Department of Microbiology & Immunology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1,550 NW 10th Avenue, 109 Papanicolau Building, Miami, Florida 33136, USA.  emesri@med.miami.edu

    • Enrique A. Mesri
  2. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, New York 10065, USA.  ecesarm@med.cornell.edu

    • Ethel Cesarman
  3. Cancer Research UK Viral Oncology Group, UCL Cancer Institute, Huntley Street, University College London, London WC1E 6BT, UK.  c.boshoff@ucl.ac.uk

    • Chris Boshoff

Authors

  1. Search for Enrique A. Mesri in:

  2. Search for Ethel Cesarman in:

  3. Search for Chris Boshoff in:

Competing interests

The authors declare no competing financial interests.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrc2888

Further reading